Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4302 Target Snapshot

ATP-dependent translocase ABCB1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
6,413Compounds
2,968Assays
109Approved Drugs
4,413.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

ATP-dependent translocase ABCB1 shows late clinical disease relevance led by leukemia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P08183. Start with leukemia, then reuse UniProt P08183 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with leukemia, then reuse UniProt P08183 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
leukemia

ATP-dependent translocase ABCB1 shows late clinical disease relevance led by leukemia. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with leukemia because it currently carries late clinical support. Linked drugs include VALSPODAR, ZOSUQUIDAR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats ATP-dependent translocase ABCB1 as ChEMBL target CHEMBL4302, mapped to UniProt P08183. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
ATP-dependent translocase ABCB1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4302
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08183
ATP-dependent translocase ABCB1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether ATP-dependent translocase ABCB1 is the right protein anchor across sources, using UniProt P08183 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why leukemia is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameATP-dependent translocase ABCB1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP08183
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelATP-dependent translocase ABCB1
UniProt AccessionP08183
Component TypeProtein
Sequence Length1280 aa

ATP-dependent translocase ABCB1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as ATP-dependent translocase ABCB1, mapped to UniProt P08183. Sequence length is 1280 aa.

Mapped IDP08183
Review nameATP-dependent translocase ABCB1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

ATP-dependent translocase ABCB1 shows late clinical disease relevance led by leukemia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
leukemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugVALSPODAR
Linked drugZOSUQUIDAR
Late clinical Phase III
acute basophilic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugVALSPODAR
Late clinical Phase III
acute erythroleukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugVALSPODAR
Late clinical Phase III
acute megakaryoblastic leukaemia
1 linked drug · 1 direct · 1 efficacy
Linked drugVALSPODAR
Late clinical Phase III
acute monocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugVALSPODAR
Late clinical Phase III
acute myeloblastic leukemia with maturation
1 linked drug · 1 direct · 1 efficacy
Linked drugVALSPODAR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with leukemia because it currently carries late clinical support. Linked drugs include VALSPODAR, ZOSUQUIDAR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseleukemia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

109
Approved
21
Phase III
22
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC502,604.0
KI326.0
EC501,429.0
KD54.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2134144 10.99 EC50 0.01015 Preclinical
CHEMBL2136603 10.99 EC50 0.01026 Preclinical
CHEMBL2132650 10.98 EC50 0.01046 Preclinical
CHEMBL2138767 10.98 EC50 0.01057 Preclinical
CHEMBL2132526 10.96 EC50 0.01096 Preclinical
CHEMBL2136710 10.93 EC50 0.01184 Preclinical
CHEMBL2137849 10.93 EC50 0.01177 Preclinical
CHEMBL1900518 10.89 EC50 0.01283 Preclinical
CHEMBL2132316 10.87 EC50 0.01351 Preclinical
CHEMBL2135811 10.87 EC50 0.01349 Preclinical
Distribution

pChEMBL Value Distribution

635
5.0
667
5.5
638
6.0
411
6.5
250
7.0
147
7.5
121
8.0
23
8.5
19
9.0
9
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
CERITINIB
CHEMBL2403108
Approved 2014
Properties Compare Identifier
NINTEDANIB
CHEMBL502835
Approved 2014
Properties Compare Identifier
TRAMETINIB
CHEMBL2103875
Approved 2013
Properties Compare Identifier
ARIPIPRAZOLE
CHEMBL1112
Approved 2002
Properties Compare Identifier
IMATINIB
CHEMBL941
Approved 2001
Properties Compare Identifier
NELFINAVIR
CHEMBL584
Approved 1997
Properties Compare Identifier
ITRACONAZOLE
CHEMBL64391
Approved 1992
Properties Compare Identifier
PROPAFENONE
CHEMBL631
Approved 1989
Properties Compare Identifier
NICARDIPINE
CHEMBL1484
Approved 1988
Properties Compare Identifier
ASTEMIZOLE
CHEMBL296419
Approved 1988
Properties Compare Identifier
CLOFAZIMINE
CHEMBL1292
Approved 1986
Properties Compare Identifier
PIMOZIDE
CHEMBL1423
Approved 1984
Properties Compare Identifier
CYCLOSPORINE
CHEMBL160
Approved 1983
Properties Compare Identifier
VERAPAMIL
CHEMBL6966
Approved 1981
Properties Compare Identifier
KETOCONAZOLE
CHEMBL157101
Approved 1981
Properties Compare Identifier
TAMOXIFEN
CHEMBL83
Approved 1977
Properties Compare Identifier
DOXORUBICIN
CHEMBL53463
Approved 1974
Properties Compare Identifier
HALOPERIDOL
CHEMBL54
Approved 1967
Properties Compare Identifier
VINBLASTINE
CHEMBL159
Approved 1965
Properties Compare Identifier
RESERPINE
CHEMBL772
Approved 1960
Properties Compare Identifier
CHLORPROMAZINE
CHEMBL71
Approved 1957
Properties Compare Identifier
QUINIDINE
CHEMBL1294
Approved 1950
Properties Compare Identifier
SULFASALAZINE
CHEMBL421
Approved 1950
Properties Compare Identifier
Assay Landscape

Assay Landscape

3,015
Total Assays
2,330
Tested Compounds
3
Assay Types
Binding — 2,089 assays, 2,330 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1,867 2,038 6.0
single protein format 105 130 5.8
assay format 53 100 5.9
tissue-based format 40 54 6.0
cell membrane format 12 8 5.4
microsome format 12 0 —
Functional — 746 assays, 338 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 666 212 5.2
cell membrane format 52 4 6.3
assay format 18 122 8.2
organism-based format 6 0 —
subcellular format 2 0 —
tissue-based format 2 0 —
ADME — 180 assays, 6 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 142 5 5.8
single protein format 36 1 4.6
assay format 1 0 —
cell membrane format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine